^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiEn (rezvilutamide)

    i
    Other names: SHR3680, SHR 3680, SHR-3680
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Androgen receptor inhibitor
    Related drugs:
    Associations

    News

    Trials
    9d
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    13d
    A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    AiRuiEn (rezvilutamide)
    17d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • GSK5764227
    23d
    Primary high-grade urothelial carcinoma of the prostate combined with acinar adenocarcinoma: first rare case report and treatment experience summary. (PubMed, Front Oncol)
    Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.
    Journal
    |
    GATA3 (GATA binding protein 3)
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide)
    2ms
    RWS-GU001: Real-world Study on Preoperative Application of Rezvilutamide (clinicaltrials.gov)
    P=N/A, N=115, Not yet recruiting, Shanghai Pudong New Area Gongli Hospital
    New trial • Real-world evidence
    |
    AiRuiEn (rezvilutamide)
    4ms
    An open-label, parallel-cohort, multicenter clinical study of Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (ChiCTR2400093262)
    P4, N=100, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University | Initiation date: Dec 2024 --> Apr 2025
    Trial initiation date
    |
    docetaxel • AiRuiEn (rezvilutamide)
    4ms
    Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=20, Enrolling by invitation, Zhujiang Hospital
    New trial
    |
    docetaxel • abiraterone acetate • AiRuiEn (rezvilutamide)
    4ms
    Exploratory Study of Rezvilutamide Combined with ADT as Neoadjuvant Therapy for Patients with Locally Advanced Prostate Cancer (ChiCTR2500106983)
    P4, N=68, Not yet recruiting, The First Affiliated Hospital of AFMU (Xijing Hospital); The First Affiliated Hospital of AFMU (Xijing Hospital)
    New P4 trial
    |
    AiRuiEn (rezvilutamide)
    5ms
    A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC (clinicaltrials.gov)
    P2, N=20, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=144 --> 20 | Active, not recruiting --> Terminated; The sponsor's R&D strategy is adjusted.
    Enrollment change • Trial termination
    |
    docetaxel • abiraterone acetate • AiRuiYi (fluzoparib) • AiRuiEn (rezvilutamide)
    6ms
    A multicenter real-world study on the treatment of prostate cancer with Rezvilutamide Tablets (ChiCTR2500102249)
    P4, N=500, Not yet recruiting, QingHai University Affiliated Hospital; QingHai University Affiliated Hospital
    New P4 trial • Real-world evidence
    |
    AiRuiEn (rezvilutamide)
    7ms
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Recruiting, Fudan University | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    8ms
    Real world research on Rezvilutamide (ChiCTR2500096749)
    P=N/A, N=112, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    AiRuiEn (rezvilutamide)